Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>HSBC Research Positive on LT Growth of CN Biotech, Favors INNOVENT BIO/ HANSOH PHARMA
Recommend 52 Positive 76 Negative 29 |
||||
|
||||
|
HSBC Global Research's report said that the White House is reportedly drafting a proposal that may affect the external licensing business development between Chinese generic and innovative drugs companies and U.S. companies. Although specific details have not been released, the related policy may involve stricter scrutiny on the licensing cooperation of innovative drugs between Chinese and American companies, sparking market concerns. The broker held a positive view on the long-term growth prospects of the biotech industry and believed that the trend of external licensing by mainland pharmaceutical companies is difficult to stop. It favored INNOVENT BIO (01801.HK) and HANSOH PHARMA (03692.HK), with target prices of HKD110 and HKD47 respectively, both rated as Buy in light of their strong domestic sales, early-stage R&D pipelines supporting long-term growth, and sufficient operating capital. AASTOCKS Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
